|
|
|
|
|
|
|
 With the acquisition of the Swedish pharmaceutical company Neopharma and the marketing rights of Duodopa®, Solvay Pharmaceuticals has become active in another therapeutic area. Duodopa® is specifically appropriate for patients with advanced stage of Parkinson’s disease (movement disorder), where oral treatments are no longer effective and are typically associated with severe motor fluctuations. Duodopa has been approved in all EU countries plus Norway, Switzerland and now Canada.
Unique delivery system
duodopa® is a levodopa/carbidopa combination. It is given inside the upper intestine via a small tube inserted directly into the first part of the small bowel, or duodenum. The unique delivery system with a programmable pump allows the physician and patient to individually tune the delivery of active ingredients, suspended as stable gel from a cassette worn outside the body. Better control of body movements can be achieved resulting in many patients becoming more functional in their daily lives.
Parkinson disease affects both men and women in almost equal numbers. It shows no social, ethnic, economic or geographic boundaries. Of all the neurodegenerative disorders it is second to Alzheimer’s disease in numbers of cases, with more that 1.3 million patients suffering from it in major countries.
While the condition usually develops after the age of 65, 15% of those diagnosed are under 50.
Visit our website www.duodopa.com for more information.
|
|
|
|
|
|
